Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Structure and function of the insulin receptor

Jonathan Whittaker, MD, MRCP
Section Editor
Irl B Hirsch, MD
Deputy Editor
Jean E Mulder, MD


Insulin initiates its cellular responses by binding to its cellular receptor, a transmembrane, multi-subunit glycoprotein that contains insulin-stimulated tyrosine kinase activity [1]. The cellular content of insulin receptors is variable, with the highest level of expression in cells that are most responsive to insulin for glucose, lipid, and protein metabolism, especially adipose, skeletal muscle, and liver. Initially identified over 25 years ago [2], the insulin receptor cDNA was cloned in 1985 [3,4]. Crystal structures of its protein tyrosine and of its extracellular domains were determined in 1994 [5] and 2006 [6], respectively. Since insulin has profound importance in metabolic control, studies of its receptor protein have been the subject of intense investigation [7].


Receptor gene and mRNA — The insulin receptor gene maps to human chromosome 19 and spans more than 150 kilobases (kb) [8]. The 22 exons of the receptor gene are transcribed into several mRNA species ranging from 4.2 to 9.5 kb in length due to variation in their 3'-untranslated regions [9]. Exon 11, which encodes a 12 amino acid segment localized to the C-terminus of the α-subunit, is subject to tissue-specific alternative splicing in a pattern conserved between humans and lower mammals (figure 1) [10-12].

The abundance of receptor mRNA and protein are up-regulated by differentiation of adipocyte and muscle precursor cells as they acquire an insulin-sensitive phenotype [13]. In some cells, exposure to insulin reduces receptor mRNA abundance, which may play a role in regulation of receptor number in vivo [14,15]. In rare cases of severe insulin resistance due to mutations in the receptor gene, extreme reduction in receptor abundance has been shown [16]. However, altered receptor abundance is not believed to play a major role in common forms of insulin resistance in obesity or type 2 diabetes.

The primary translation product of the insulin receptor mRNA is a linear α-ß sequence of the insulin receptor precursor (proreceptor). The signal sequence of 27 hydrophobic amino acids at the N-terminus of the α-subunit allows the receptor to enter the endoplasmic reticulum, during which process the signal peptide is cleaved. The proreceptor is further proteolytically-processed by furin in the Golgi apparatus into distinct α and ß-subunits at a cleavage site consisting of four basic amino acids (Arg-Lys-Arg-Arg) [17-20], apparently after disulfide linkage of two proreceptor molecules [21].

Receptor structure — The receptor is composed of two extracellular α-subunits that are each linked to a ß-subunit and to each other by disulfide bonds (figure 2). Reduction of the bonds that link the α-subunits produces an α-ß monomer that binds insulin with reduced affinity [22,23] and that is devoid of insulin stimulated tyrosine kinase activity [24,25]. Reconstitution of such hetero-dimers into hetero-tetramers restores both high affinity insulin binding and insulin stimulated kinase activity [24,25].

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Aug 19, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Kido Y, Nakae J, Accili D. Clinical review 125: The insulin receptor and its cellular targets. J Clin Endocrinol Metab 2001; 86:972.
  2. Freychet P, Roth J, Neville DM Jr. Insulin receptors in the liver: specific binding of ( 125 I)insulin to the plasma membrane and its relation to insulin bioactivity. Proc Natl Acad Sci U S A 1971; 68:1833.
  3. Ebina Y, Ellis L, Jarnagin K, et al. The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signalling. Cell 1985; 40:747.
  4. Ullrich A, Bell JR, Chen EY, et al. Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 1985; 313:756.
  5. Hubbard SR, Wei L, Ellis L, Hendrickson WA. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 1994; 372:746.
  6. Lou M, Garrett TP, McKern NM, et al. The first three domains of the insulin receptor differ structurally from the insulin-like growth factor 1 receptor in the regions governing ligand specificity. Proc Natl Acad Sci U S A 2006; 103:12429.
  7. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001; 414:799.
  8. Seino S, Seino M, Nishi S, Bell GI. Structure of the human insulin receptor gene and characterization of its promoter. Proc Natl Acad Sci U S A 1989; 86:114.
  9. Goldstein BJ, Kahn CR. Analysis of mRNA heterogeneity by ribonuclease H mapping: application to the insulin receptor. Biochem Biophys Res Commun 1989; 159:664.
  10. Seino S, Bell GI. Alternative splicing of human insulin receptor messenger RNA. Biochem Biophys Res Commun 1989; 159:312.
  11. Moller DE, Yokota A, Caro JF, Flier JS. Tissue-specific expression of two alternatively spliced insulin receptor mRNAs in man. Mol Endocrinol 1989; 3:1263.
  12. Goldstein BJ, Dudley AL. The rat insulin receptor: primary structure and conservation of tissue-specific alternative messenger RNA splicing. Mol Endocrinol 1990; 4:235.
  13. Sibley E, Kastelic T, Kelly TJ, Lane MD. Characterization of the mouse insulin receptor gene promoter. Proc Natl Acad Sci U S A 1989; 86:9732.
  14. Mamula PW, McDonald AR, Brunetti A, et al. Regulating insulin-receptor-gene expression by differentiation and hormones. Diabetes Care 1990; 13:288.
  15. Gavin JR 3rd, Roth J, Neville DM Jr, et al. Insulin-dependent regulation of insulin receptor concentrations: a direct demonstration in cell culture. Proc Natl Acad Sci U S A 1974; 71:84.
  16. Imano E, Kadowaki H, Kadowaki T, et al. Two patients with insulin resistance due to decreased levels of insulin-receptor mRNA. Diabetes 1991; 40:548.
  17. Alarcón C, Cheatham B, Lincoln B, et al. A Kex2-related endopeptidase activity present in rat liver specifically processes the insulin proreceptor. Biochem J 1994; 301 ( Pt 1):257.
  18. Bass J, Turck C, Rouard M, Steiner DF. Furin-mediated processing in the early secretory pathway: sequential cleavage and degradation of misfolded insulin receptors. Proc Natl Acad Sci U S A 2000; 97:11905.
  19. Bravo DA, Gleason JB, Sanchez RI, et al. Accurate and efficient cleavage of the human insulin proreceptor by the human proprotein-processing protease furin. Characterization and kinetic parameters using the purified, secreted soluble protease expressed by a recombinant baculovirus. J Biol Chem 1994; 269:25830.
  20. Robertson BJ, Moehring JM, Moehring TJ. Defective processing of the insulin receptor in an endoprotease-deficient Chinese hamster cell strain is corrected by expression of mouse furin. J Biol Chem 1993; 268:24274.
  21. Olson TS, Lane MD. Post-translational acquisition of insulin binding activity by the insulin proreceptor. Correlation to recognition by autoimmune antibody. J Biol Chem 1987; 262:6816.
  22. Salzman A, Wan CF, Rubin CS. Biogenesis, transit, and functional properties of the insulin proreceptor and modified insulin receptors in 3T3-L1 adipocytes. Use of monensin to probe proreceptor cleavage and generate altered receptor subunits. Biochemistry 1984; 23:6555.
  23. Sweet LJ, Morrison BD, Pessin JE. Isolation of functional alpha beta heterodimers from the purified human placental alpha 2 beta 2 heterotetrameric insulin receptor complex. A structural basis for insulin binding heterogeneity. J Biol Chem 1987; 262:6939.
  24. Böni-Schnetzler M, Kaligian A, DelVecchio R, Pilch PF. Ligand-dependent intersubunit association within the insulin receptor complex activates its intrinsic kinase activity. J Biol Chem 1988; 263:6822.
  25. Morrison BD, Swanson ML, Sweet LJ, Pessin JE. Insulin-dependent covalent reassociation of isolated alpha beta heterodimeric insulin receptors into an alpha 2 beta 2 heterotetrameric disulfide-linked complex. J Biol Chem 1988; 263:7806.
  26. Sparrow LG, Lawrence MC, Gorman JJ, et al. N-linked glycans of the human insulin receptor and their distribution over the crystal structure. Proteins 2008; 71:426.
  27. Elleman TC, Frenkel MJ, Hoyne PA, et al. Mutational analysis of the N-linked glycosylation sites of the human insulin receptor. Biochem J 2000; 347 Pt 3:771.
  28. Sparrow LG, Gorman JJ, Strike PM, et al. The location and characterisation of the O-linked glycans of the human insulin receptor. Proteins 2007; 66:261.
  29. McKern NM, Lawrence MC, Streltsov VA, et al. Structure of the insulin receptor ectodomain reveals a folded-over conformation. Nature 2006; 443:218.
  30. Croll TI, Smith BJ, Margetts MB, et al. Higher-Resolution Structure of the Human Insulin Receptor Ectodomain: Multi-Modal Inclusion of the Insert Domain. Structure 2016; 24:469.
  31. Pilch PF, Czech MP. The subunit structure of the high affinity insulin receptor. Evidence for a disulfide-linked receptor complex in fat cell and liver plasma membranes. J Biol Chem 1980; 255:1722.
  32. Benecke H, Flier JS, Moller DE. Alternatively spliced variants of the insulin receptor protein. Expression in normal and diabetic human tissues. J Clin Invest 1992; 89:2066.
  33. Mosthaf L, Grako K, Dull TJ, et al. Functionally distinct insulin receptors generated by tissue-specific alternative splicing. EMBO J 1990; 9:2409.
  34. Yamaguchi Y, Flier JS, Yokota A, et al. Functional properties of two naturally occurring isoforms of the human insulin receptor in Chinese hamster ovary cells. Endocrinology 1991; 129:2058.
  35. Vogt B, Carrascosa JM, Ermel B, et al. The two isotypes of the human insulin receptor (HIR-A and HIR-B) follow different internalization kinetics. Biochem Biophys Res Commun 1991; 177:1013.
  36. Kellerer M, Lammers R, Ermel B, et al. Distinct alpha-subunit structures of human insulin receptor A and B variants determine differences in tyrosine kinase activities. Biochemistry 1992; 31:4588.
  37. Savkur RS, Philips AV, Cooper TA. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet 2001; 29:40.
  38. Sell SM, Reese D, Ossowski VM. Insulin-inducible changes in insulin receptor mRNA splice variants. J Biol Chem 1994; 269:30769.
  39. De Meyts P. The structural basis of insulin and insulin-like growth factor-I receptor binding and negative co-operativity, and its relevance to mitogenic versus metabolic signalling. Diabetologia 1994; 37 Suppl 2:S135.
  40. de Meyts P, Roth J, Neville DM Jr, et al. Insulin interactions with its receptors: experimental evidence for negative cooperativity. Biochem Biophys Res Commun 1973; 55:154.
  41. DeMeyts P, Bainco AR, Roth J. Site-site interactions among insulin receptors. Characterization of the negative cooperativity. J Biol Chem 1976; 251:1877.
  42. Siegfried W. Perspectives in gene therapy with recombinant adenoviruses. Exp Clin Endocrinol 1993; 101:7.
  43. De Meyts P, Gu JL, Shymko RM, et al. Identification of a ligand-binding region of the human insulin receptor encoded by the second exon of the gene. Mol Endocrinol 1990; 4:409.
  44. Schumacher R, Soos MA, Schlessinger J, et al. Signaling-competent receptor chimeras allow mapping of major insulin receptor binding domain determinants. J Biol Chem 1993; 268:1087.
  45. Kasuga M, Karlsson FA, Kahn CR. Insulin stimulates the phosphorylation of the 95,000-dalton subunit of its own receptor. Science 1982; 215:185.
  46. Mynarcik DC, Yu GQ, Whittaker J. Alanine-scanning mutagenesis of a C-terminal ligand binding domain of the insulin receptor alpha subunit. J Biol Chem 1996; 271:2439.
  47. Whittaker J, Whittaker L. Characterization of the functional insulin binding epitopes of the full-length insulin receptor. J Biol Chem 2005; 280:20932.
  48. Williams PF, Mynarcik DC, Yu GQ, Whittaker J. Mapping of an NH2-terminal ligand binding site of the insulin receptor by alanine scanning mutagenesis. J Biol Chem 1995; 270:3012.
  49. Kristensen C, Andersen AS, Ostergaard S, et al. Functional reconstitution of insulin receptor binding site from non-binding receptor fragments. J Biol Chem 2002; 277:18340.
  50. Kristensen C, Wiberg FC, Andersen AS. Specificity of insulin and insulin-like growth factor I receptors investigated using chimeric mini-receptors. Role of C-terminal of receptor alpha subunit. J Biol Chem 1999; 274:37351.
  51. Kristensen C, Wiberg FC, Schäffer L, Andersen AS. Expression and characterization of a 70-kDa fragment of the insulin receptor that binds insulin. Minimizing ligand binding domain of the insulin receptor. J Biol Chem 1998; 273:17780.
  52. Menting JG, Ward CW, Margetts MB, Lawrence MC. A thermodynamic study of ligand binding to the first three domains of the human insulin receptor: relationship between the receptor alpha-chain C-terminal peptide and the site 1 insulin mimetic peptides. Biochemistry 2009; 48:5492.
  53. Smith BJ, Huang K, Kong G, et al. Structural resolution of a tandem hormone-binding element in the insulin receptor and its implications for design of peptide agonists. Proc Natl Acad Sci U S A 2010; 107:6771.
  54. Menting JG, Whittaker J, Margetts MB, et al. How insulin engages its primary binding site on the insulin receptor. Nature 2013; 493:241.
  55. Hao C, Whittaker L, Whittaker J. Characterization of a second ligand binding site of the insulin receptor. Biochem Biophys Res Commun 2006; 347:334.
  56. Whittaker L, Hao C, Fu W, Whittaker J. High-affinity insulin binding: insulin interacts with two receptor ligand binding sites. Biochemistry 2008; 47:12900.
  57. Chan SJ, Nakagawa S, Steiner DF. Complementation analysis demonstrates that insulin cross-links both alpha subunits in a truncated insulin receptor dimer. J Biol Chem 2007; 282:13754.
  58. Luo RZ, Beniac DR, Fernandes A, et al. Quaternary structure of the insulin-insulin receptor complex. Science 1999; 285:1077.
  59. Vashisth H, Abrams CF. Docking of insulin to a structurally equilibrated insulin receptor ectodomain. Proteins 2010; 78:1531.
  60. Whittaker J, Whittaker LJ, Roberts CT Jr, et al. α-Helical element at the hormone-binding surface of the insulin receptor functions as a signaling element to activate its tyrosine kinase. Proc Natl Acad Sci U S A 2012; 109:11166.
  61. Frattali AL, Treadway JL, Pessin JE. Evidence supporting a passive role for the insulin receptor transmembrane domain in insulin-dependent signal transduction. J Biol Chem 1991; 266:9829.
  62. Yamada K, Goncalves E, Kahn CR, Shoelson SE. Substitution of the insulin receptor transmembrane domain with the c-neu/erbB2 transmembrane domain constitutively activates the insulin receptor kinase in vitro. J Biol Chem 1992; 267:12452.
  63. Lee J, Miyazaki M, Romeo GR, Shoelson SE. Insulin receptor activation with transmembrane domain ligands. J Biol Chem 2014; 289:19769.
  64. Kavran JM, McCabe JM, Byrne PO, et al. How IGF-1 activates its receptor. Elife 2014; 3.
  65. Shoelson SE, White MF, Kahn CR. Tryptic activation of the insulin receptor. Proteolytic truncation of the alpha-subunit releases the beta-subunit from inhibitory control. J Biol Chem 1988; 263:4852.
  66. Wei L, Hubbard SR, Hendrickson WA, Ellis L. Expression, characterization, and crystallization of the catalytic core of the human insulin receptor protein-tyrosine kinase domain. J Biol Chem 1995; 270:8122.
  67. Cabail MZ, Li S, Lemmon E, et al. The insulin and IGF1 receptor kinase domains are functional dimers in the activated state. Nat Commun 2015; 6:6406.
  68. Olefsky JM. The insulin receptor. A multifunctional protein. Diabetes 1990; 39:1009.
  69. Hubbard SR, Mohammadi M, Schlessinger J. Autoregulatory mechanisms in protein-tyrosine kinases. J Biol Chem 1998; 273:11987.
  70. Hubbard SR, Till JH. Protein tyrosine kinase structure and function. Annu Rev Biochem 2000; 69:373.
  71. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103:211.
  72. White MF. IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab 2002; 283:E413.
  73. Kido Y, Burks DJ, Withers D, et al. Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2. J Clin Invest 2000; 105:199.
  74. Kubota N, Terauchi Y, Tobe K, et al. Insulin receptor substrate 2 plays a crucial role in beta cells and the hypothalamus. J Clin Invest 2004; 114:917.
  75. Lin X, Taguchi A, Park S, et al. Dysregulation of insulin receptor substrate 2 in beta cells and brain causes obesity and diabetes. J Clin Invest 2004; 114:908.
  76. Hanks SK, Quinn AM, Hunter T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 1988; 241:42.
  77. Chou CK, Dull TJ, Russell DS, et al. Human insulin receptors mutated at the ATP-binding site lack protein tyrosine kinase activity and fail to mediate postreceptor effects of insulin. J Biol Chem 1987; 262:1842.
  78. White MF, Livingston JN, Backer JM, et al. Mutation of the insulin receptor at tyrosine 960 inhibits signal transmission but does not affect its tyrosine kinase activity. Cell 1988; 54:641.
  79. Rajagopalan M, Neidigh JL, McClain DA. Amino acid sequences Gly-Pro-Leu-Tyr and Asn-Pro-Glu-Tyr in the submembranous domain of the insulin receptor are required for normal endocytosis. J Biol Chem 1991; 266:23068.
  80. White MF, Shoelson SE, Keutmann H, Kahn CR. A cascade of tyrosine autophosphorylation in the beta-subunit activates the phosphotransferase of the insulin receptor. J Biol Chem 1988; 263:2969.
  81. Flores-Riveros JR, Sibley E, Kastelic T, Lane MD. Substrate phosphorylation catalyzed by the insulin receptor tyrosine kinase. Kinetic correlation to autophosphorylation of specific sites in the beta subunit. J Biol Chem 1989; 264:21557.
  82. Lee J, O'Hare T, Pilch PF, Shoelson SE. Insulin receptor autophosphorylation occurs asymmetrically. J Biol Chem 1993; 268:4092.
  83. Zhang B, Roth RA. Binding properties of chimeric insulin receptors containing the cysteine-rich domain of either the insulin-like growth factor I receptor or the insulin receptor related receptor. Biochemistry 1991; 30:5113.
  84. Zhang B, Tavaré JM, Ellis L, Roth RA. The regulatory role of known tyrosine autophosphorylation sites of the insulin receptor kinase domain. An assessment by replacement with neutral and negatively charged amino acids. J Biol Chem 1991; 266:990.
  85. Wilden PA, Siddle K, Haring E, et al. The role of insulin receptor kinase domain autophosphorylation in receptor-mediated activities. Analysis with insulin and anti-receptor antibodies. J Biol Chem 1992; 267:13719.
  86. Feener EP, Backer JM, King GL, et al. Insulin stimulates serine and tyrosine phosphorylation in the juxtamembrane region of the insulin receptor. J Biol Chem 1993; 268:11256.
  87. Faria TN, Blakesley VA, Kato H, et al. Role of the carboxyl-terminal domains of the insulin and insulin-like growth factor I receptors in receptor function. J Biol Chem 1994; 269:13922.
  88. Tornqvist HE, Pierce MW, Frackelton AR, et al. Identification of insulin receptor tyrosine residues autophosphorylated in vitro. J Biol Chem 1987; 262:10212.
  89. Kaliman P, Baron V, Alengrin F, et al. The insulin receptor C-terminus is involved in regulation of the receptor kinase activity. Biochemistry 1993; 32:9539.
  90. Smith RM, Sasaoka T, Shah N, et al. A truncated human insulin receptor missing the COOH-terminal 365 amino acid residues does not undergo insulin-mediated receptor migration or aggregation. Endocrinology 1993; 132:1453.
  91. Thies RS, Ullrich A, McClain DA. Augmented mitogenesis and impaired metabolic signaling mediated by a truncated insulin receptor. J Biol Chem 1989; 264:12820.
  92. Myers MG, Backer JM, Siddle K, White MF. The insulin receptor functions normally in Chinese hamster ovary cells after truncation of the C terminus. J Biol Chem 1991; 266:10616.
  93. Treadway JL, Morrison BD, Soos MA, et al. Transdominant inhibition of tyrosine kinase activity in mutant insulin/insulin-like growth factor I hybrid receptors. Proc Natl Acad Sci U S A 1991; 88:214.
  94. Frattali AL, Treadway JL, Pessin JE. Transmembrane signaling by the human insulin receptor kinase. Relationship between intramolecular beta subunit trans- and cis-autophosphorylation and substrate kinase activation. J Biol Chem 1992; 267:19521.
  95. Moller DE, Yokota A, White MF, et al. A naturally occurring mutation of insulin receptor alanine 1134 impairs tyrosine kinase function and is associated with dominantly inherited insulin resistance. J Biol Chem 1990; 265:14979.
  96. King GL, Rechler MM, Kahn CR. Interactions between the receptors for insulin and the insulin-like growth factors on adipocytes. J Biol Chem 1982; 257:10001.
  97. Moxham CP, Duronio V, Jacobs S. Insulin-like growth factor I receptor beta-subunit heterogeneity. Evidence for hybrid tetramers composed of insulin-like growth factor I and insulin receptor heterodimers. J Biol Chem 1989; 264:13238.
  98. Bailyes EM, Navé BT, Soos MA, et al. Insulin receptor/IGF-I receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting. Biochem J 1997; 327 ( Pt 1):209.
  99. Slaaby R, Schäffer L, Lautrup-Larsen I, et al. Hybrid receptors formed by insulin receptor (IR) and insulin-like growth factor I receptor (IGF-IR) have low insulin and high IGF-1 affinity irrespective of the IR splice variant. J Biol Chem 2006; 281:25869.
  100. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007; 28:20.
  101. Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 2007; 6:1.
  102. Gottschalk WK. The pathway mediating insulin's effects on pyruvate dehydrogenase bypasses the insulin receptor tyrosine kinase. J Biol Chem 1991; 266:8814.
  103. Hawley DM, Maddux BA, Patel RG, et al. Insulin receptor monoclonal antibodies that mimic insulin action without activating tyrosine kinase. J Biol Chem 1989; 264:2438.
  104. Steele-Perkins G, Roth RA. Insulin-mimetic anti-insulin receptor monoclonal antibodies stimulate receptor kinase activity in intact cells. J Biol Chem 1990; 265:9458.
  105. Moller DE, Benecke H, Flier JS. Biologic activities of naturally occurring human insulin receptor mutations. Evidence that metabolic effects of insulin can be mediated by a kinase-deficient insulin receptor mutant. J Biol Chem 1991; 266:10995.
  106. Takayama S, White MF, Kahn CR. Phorbol ester-induced serine phosphorylation of the insulin receptor decreases its tyrosine kinase activity. J Biol Chem 1988; 263:3440.
  107. Chin JE, Dickens M, Tavare JM, Roth RA. Overexpression of protein kinase C isoenzymes alpha, beta I, gamma, and epsilon in cells overexpressing the insulin receptor. Effects on receptor phosphorylation and signaling. J Biol Chem 1993; 268:6338.
  108. Stadtmauer L, Rosen OM. Increasing the cAMP content of IM-9 cells alters the phosphorylation state and protein kinase activity of the insulin receptor. J Biol Chem 1986; 261:3402.
  109. Lewis RE, Cao L, Perregaux D, Czech MP. Threonine 1336 of the human insulin receptor is a major target for phosphorylation by protein kinase C. Biochemistry 1990; 29:1807.
  110. Zick Y. Ser/Thr phosphorylation of IRS proteins: a molecular basis for insulin resistance. Sci STKE 2005; 2005:pe4.
  111. Posner BI, Kahn MN, Bergeron JJ. Internalization of insulin: structures involved and significance. Adv Exp Med Biol 1985; 189:159.
  112. Duckworth WC. Insulin degradation: mechanisms, products, and significance. Endocr Rev 1988; 9:319.
  113. Backer JM, Shoelson SE, Haring E, White MF. Insulin receptors internalize by a rapid, saturable pathway requiring receptor autophosphorylation and an intact juxtamembrane region. J Cell Biol 1991; 115:1535.
  114. Backer JM, Kahn CR, White MF. The dissociation and degradation of internalized insulin occur in the endosomes of rat hepatoma cells. J Biol Chem 1990; 265:14828.
  115. Doherty JJ 2nd, Kay DG, Lai WH, et al. Selective degradation of insulin within rat liver endosomes. J Cell Biol 1990; 110:35.
  116. Khan MN, Baquiran G, Brule C, et al. Internalization and activation of the rat liver insulin receptor kinase in vivo. J Biol Chem 1989; 264:12931.
  117. Wilden PA, Kahn CR, Siddle K, White MF. Insulin receptor kinase domain autophosphorylation regulates receptor enzymatic function. J Biol Chem 1992; 267:16660.
  118. Mooney RA, Anderson DL. Phosphorylation of the insulin receptor in permeabilized adipocytes is coupled to a rapid dephosphorylation reaction. J Biol Chem 1989; 264:6850.
  119. Goldstein, BJ. Protein-tyrosine phosphatases and the regulation of insulin action. LeRoith D, Taylor SI, Olefsky JM, editors. Diabetes Mellitus: A Fundamental and Clinical Text 2003; 3:255.
  120. Bevan AP, Drake PG, Yale JF, et al. Peroxovanadium compounds: biological actions and mechanism of insulin-mimesis. Mol Cell Biochem 1995; 153:49.
  121. Fantus IG, Tsiani E. Multifunctional actions of vanadium compounds on insulin signaling pathways: evidence for preferential enhancement of metabolic versus mitogenic effects. Mol Cell Biochem 1998; 182:109.
  122. Goldwaser I, Gefel D, Gershonov E, et al. Insulin-like effects of vanadium: basic and clinical implications. J Inorg Biochem 2000; 80:21.
  123. Asante-Appiah E, Kennedy BP. Protein tyrosine phosphatases: the quest for negative regulators of insulin action. Am J Physiol Endocrinol Metab 2003; 284:E663.
  124. Goldstein BJ, Mahadev K, Wu X. Redox paradox: insulin action is facilitated by insulin-stimulated reactive oxygen species with multiple potential signaling targets. Diabetes 2005; 54:311.
  125. Andersen JN, Mortensen OH, Peters GH, et al. Structural and evolutionary relationships among protein tyrosine phosphatase domains. Mol Cell Biol 2001; 21:7117.
  126. Goldstein BJ. Protein-tyrosine phosphatases: emerging targets for therapeutic intervention in type 2 diabetes and related states of insulin resistance. J Clin Endocrinol Metab 2002; 87:2474.
  127. Tonks NK. PTP1B: from the sidelines to the front lines! FEBS Lett 2003; 546:140.
  128. Ramachandran C, Kennedy BP. Protein tyrosine phosphatase 1B: a novel target for type 2 diabetes and obesity. Curr Top Med Chem 2003; 3:749.
  129. Klaman LD, Boss O, Peroni OD, et al. Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol Cell Biol 2000; 20:5479.
  130. Elchebly M, Payette P, Michaliszyn E, et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 1999; 283:1544.
  131. Zabolotny JM, Bence-Hanulec KK, Stricker-Krongrad A, et al. PTP1B regulates leptin signal transduction in vivo. Dev Cell 2002; 2:489.
  132. Zinker BA, Rondinone CM, Trevillyan JM, et al. PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc Natl Acad Sci U S A 2002; 99:11357.
  133. Galic S, Hauser C, Kahn BB, et al. Coordinated regulation of insulin signaling by the protein tyrosine phosphatases PTP1B and TCPTP. Mol Cell Biol 2005; 25:819.
  134. Pandey SK, Yu XX, Watts LM, et al. Reduction of low molecular weight protein-tyrosine phosphatase expression improves hyperglycemia and insulin sensitivity in obese mice. J Biol Chem 2007; 282:14291.
  135. Dubois MJ, Bergeron S, Kim HJ, et al. The SHP-1 protein tyrosine phosphatase negatively modulates glucose homeostasis. Nat Med 2006; 12:549.
  136. Béréziat V, Kasus-Jacobi A, Perdereau D, et al. Inhibition of insulin receptor catalytic activity by the molecular adapter Grb14. J Biol Chem 2002; 277:4845.
  137. Nouaille S, Blanquart C, Zilberfarb V, et al. Interaction with Grb14 results in site-specific regulation of tyrosine phosphorylation of the insulin receptor. EMBO Rep 2006; 7:512.
  138. Cooney GJ, Lyons RJ, Crew AJ, et al. Improved glucose homeostasis and enhanced insulin signalling in Grb14-deficient mice. EMBO J 2004; 23:582.
  139. Maddux BA, Chang YN, Accili D, et al. Overexpression of the insulin receptor inhibitor PC-1/ENPP1 induces insulin resistance and hyperglycemia. Am J Physiol Endocrinol Metab 2006; 290:E746.
  140. Abate N, Chandalia M, Di Paola R, et al. Mechanisms of disease: Ectonucleotide pyrophosphatase phosphodiesterase 1 as a 'gatekeeper' of insulin receptors. Nat Clin Pract Endocrinol Metab 2006; 2:694.
  141. Poy MN, Ruch RJ, Fernstrom MA, et al. Shc and CEACAM1 interact to regulate the mitogenic action of insulin. J Biol Chem 2002; 277:1076.
  142. Najjar SM. Regulation of insulin action by CEACAM1. Trends Endocrinol Metab 2002; 13:240.
  143. Park SY, Cho YR, Kim HJ, et al. Mechanism of glucose intolerance in mice with dominant negative mutation of CEACAM1. Am J Physiol Endocrinol Metab 2006; 291:E517.